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Abstract
Background: A previous estimate of the burden of schizophrenia in Thailand relied on epidemiological estimates
from elsewhere. The aim of this study is to estimate the prevalence and disease burden of schizophrenia in
Thailand using local data sources that recently have become available.
Methods: The prevalence of schizophrenia was estimated from a community mental health survey supplemented
by a count of hospital admissions. Using data from recent meta-analyses of the risk of mortality and remission, we
derived incidence and average duration using DisMod software. We used treated disability weights based on
patient and clinician ratings from our own local survey of patients in contact with mental health services and
applied methods from Australian Burden of Disease and cost-effectiveness studies. We applied untreated disability
weights from the Global Burden of Disease (GBD) study. Uncertainty analysis was conducted using Monte Carlo
simulation.
Results: The prevalence of schizophrenia at ages 15-59 in the Thai population was 8.8 per 1,000 (95% CI: 7.2, 10.6)
with a male-to-female ratio of 1.1-to-1. The disability weights from local data were somewhat lower than the GBD
weights. The disease burden in disability-adjusted life years was similar in men (70,000; 95% CI: 64,000, 77, 000) and
women (75,000; 95% CI: 69,000, 83,000). The impact of using the lower Thai disability weights on the DALY
estimates was small in comparison to the uncertainty in prevalence.
Conclusions: Prevalence of schizophrenia was more critical to an accurate estimate of burden of disease in
Thailand than variations in disability weights.
Background
S c h i z o p h r e n i ai so n eo ft h em o s ts e v e r ea n dd i s a b l i n g
mental illnesses. It is not a common disease. However,
it has significant health, economic, and social conse-
quences. In adults, the median prevalence from a sys-
tematic review was 3.3 per 1,000, ranging from 1.3 for
the 10
th percentile to 8.2 for the 90
th percentile [1]. In
2001, schizophrenia ranked among the top 10 leading
causes of years lived with disability (YLD) worldwide
[2,3]. In Thailand in 1999, it was the eighth and ninth
leading cause of YLD in men and women, respectively,
responsible for 5% of disability from all causes [4]. Mea-
sured in disability-adjusted life years (DALYs), it ranked
as the third-largest mental disorder after depression and
anxiety disorders [4].
A p a r tf r o mt h es i g n i f i c a n th e a l t hc o n s e q u e n c e s ,t h e
health care costs of schizophrenia are also high and fre-
quently underestimated. TheW o r l dH e a l t hO r g a n i z a -
tion (WHO) estimates the direct health care costs of
schizophrenia in Western countries range between 1.6%
and 2.6% of total health care expenditures [5]. In Tai-
wan, schizophrenia accounted for 1.2% of national
health care expenditures [6]. To the best of our knowl-
edge, there are no studies reporting the cost of schizo-
phrenia in Thailand.
The burden of schizophrenia in Thailand has not been
well-established. The main reason was a lack of popula-
tion-based epidemiological data. The disease parameters
used for the 1999 Thai Burden of Disease study, such as
prevalence estimates and relative risk of death, were
extrapolated from international studies [4]. Recently,
more empirical data, including data from systematic
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the 2003 National Mental Health Survey, have become
available [7-9]. However, in the absence of incidence
and disease duration data required for burden of disease
estimates, modeling techniques are required to assist in
estimating those missing parameters [7,10].
There has been criticism of the technical basis and
value judgments used in developing the disability
weights (DW) applied in burden of disease studies (such
as the Global Burden of Disease). The main criticisms
were: (a) that a small group of international health
experts determined all DWs; and (b) that regional and
cultural differences in health state valuations were
ignored [11]. We carried out a study among Thai
patients in contact with mental health services for schi-
zophrenia to estimate severity and derive a local alterna-
tive of a treated disability weight in contrast with GBD
assumptions.
The two objectives of the present study therefore were
to (1) estimate the prevalence of schizophrenia in Thai-
land and (2) to estimate the burden of schizophrenia in
terms of DALYs.
Methods
National prevalence estimates
The national prevalence of schizophrenia was estimated
from a community mental health survey supplemented
by a count of hospital admissions at the time of the sur-
vey. The mental health survey sample included 11,700
individuals aged between 15 and 59 years living in a
residential house during the period of the survey from
June to August, 2003 [9,12].
The sampling method used in the mental health sur-
vey is described in detail elsewhere http://www.dmh.
go.th/journal/[9,12]. Data were collected in two steps.
First, respondents were screened for mental health
problems using the mental health screening question-
naire for community [12] and the Alcohol Use Disor-
der Identification Test (AUDIT) [13]. The former
instrument contains 24 questions and was developed
by Thai researchers based on their experience with
psychiatric conditions and treatments of mental disor-
ders. Subsequently, psychiatric diagnoses were assessed
in those individuals screening positive using the gen-
eral Mini International Neuropsychiatry Interview
(MINI) [14], which was translated to Thai language
[ 1 5 ] .U s i n gt h eM I N Iq u e s t i o n n a i r e ,p e o p l ew e r ea s k e d
a number of questions about unusual experiences; for
example, “Have you ever believed that people were
spying on you, or that someone was plotting against
you, or trying to hurt you?” Also, they were asked if
the beliefs and experiences they described were asso-
ciated exclusively with times when they were feeling
depressed, high, or irritable [14,15]. Data were
collected during face-to-face interviews conducted by
psychiatric nurses with at least two years of experience
with psychiatric patients.
As the mental health survey estimated the lifetime
prevalence of psychotic disorders, we adjusted the pre-
valence downward to reflect the prevalence of schizo-
phrenia only, using a 0.83 ratio of schizophrenia
(including schizoaffective disorder and schizophreniform
disorder) to all nonaffective psychotic disorders from
the study of lifetime prevalence of psychotic and bipolar
disorders in a Finnish population [16]. Although cultural
differences between Finland and Thailand limit the
applicability of this ratio, it was the only available ratio
indicating the proportion of psychotic disorders that are
schizophrenia. The proportions of cases with affective
psychoses including bipolar disorder and depressive psy-
chotic disorder in this study were estimated separately
in the Thai mental health survey [9]. The survey found
that the prevalence of manic episode was 0.4%, hypoma-
nia was 0.5%, and mood disorder with psychotic features
was 0.4%, giving an estimated prevalence of bipolar dis-
order of 1.3% [9]. It is toward the upper end of what
would be the expected prevalence of bipolar disorder. It
is therefore unlikely that we overestimated nonaffective
psychosis by counting cases of affective psychosis.
Because people living in institutions such as temples
and hospitals were excluded from the mental health sur-
vey, we combined the cases found in the survey with an
estimate of the number of people with schizophrenia
who were in a hospital during the three-month survey
period. We used the 2003 data collection system of
admissions to general hospitals and a separate dataset
for psychiatric hospital admissions collected by the
Department of Mental Health, Thailand, to estimate
hospital-based prevalence. There were 1,800 patients
with schizophrenia identified during the survey period
in general hospitals and 4,300 in the database for psy-
chiatric hospital admissions. We assumed no overlap
between cases identified in the household mental health
survey and the hospital database. Prevalent cases from
each source were combined by age and sex to give an
estimate of the overall prevalence of schizophrenia.
Incidence and disease duration
We used an Incidence-Prevalence-Mortality (IPM)
model, DisMod, to estimate the epidemiological para-
meters of schizophrenia [10]. The model assumes a cau-
sal relationship between incidence and prevalence and
takes remission, cause-specific mortality, and overall
mortality as competing risks into account to calculate
incidence and disease duration [17,18]. If three disease
parameters are defined, DisMod uses a set of mathema-
tical equations to derive an internally consistent set of
epidemiological parameters including the missing ones.
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Page 2 of 8In our case, these inputs were: (1) prevalence; (2) rela-
tive risk of mortality, and (3) remission rate.
We imposed an age pattern of prevalence estimated by
pooling data from international prevalence studies with
detailed age breakdowns identified in a recent systematic
review [7] while constraining estimates to the totals esti-
mated for ages 15-59 (Table 1). This was done for two
reasons: (1) the Thai mental health survey did not
report on prevalence in the elderly; and (2) age-specific
estimates were based on small numbers of cases and
had wide and overlapping confidence intervals (Figure
1). The relative risk of mortality in patients with schizo-
phrenia was taken from a recent meta-analysis that
reported a standardized mortality ratio for people with
schizophrenia of 2.58 in both males and females [19]. A
detailed age pattern for the standardized mortality ratio
was available from two studies and applied so that the
overall mortality ratio remained 2.58 [20,21]. As the
third input parameter, we used a pooled annual remis-
sion rate of 1.37% based on 12 studies [7].
Disability weights
The disability weights used inG B Ds t u d i e sr e f l e c tt h e
severity of nonfatal disease outcomes. Disability is
defined as “any restriction or lack of ability (resulting
from an impairment, any loss or abnormality of psycho-
logical or anatomical structure or function) to perform
an activity in the manner or within the range considered
normal for a human being” [22].
GBD studies have relied on a set of DWs that were
based on the opinions of an expert group using the per-
son trade-off method [22,23]. Placed on a disability scale
of 0 to 1, where 0 represents perfect health, DWs of
0.637 for untreated schizophrenia and 0.351 for treated
schizophrenia were used in GBD studies [22].
We present two different methods to capture the
severity of disease from a survey we carried out among
Thai people treated for schizophrenia [24]. We collected
information on disease severity from both the patients’
point of view using the six-dimensional EuroQoL Instru-
ment (EQ-5D+) measuring mobility, self-care, usual
activities, pain or discomfort, and anxiety/depression
[25] and clinicians’ ratings on the Brief Psychiatric Rat-
ing Scale Expanded version (BPRS-E) [26]. For the first
method, we used a multiplicative regression model
developed for Australian Burden of Disease studies [27].
This regression model determined the relationship
between 241 health states with EQ-5D+ descriptors and
the disability weights from the Dutch Burden of Disease
study [25,27]. Given the weights from that regression,
we mapped the EQ-5D+ scores as reported by each
patient in our survey [24] into those disability weights
[25,27]. We then computed the average disability
weights by age and sex. The second method is based on
that developed for the Assessing Cost-Effectiveness
Mental Health project in Australia to translate severity
measured as a change in BPRS-E score into a DW
[28,29]. They implemented a sliding scale between the
highest and lowest values of the Dutch disability weights
for schizophrenia into a health status measure of each
respondent from the Australian mental health survey to
calculate an average disability weight [25,28,29]. Here,
we assumed the highest and lowest BPRS-E scores in
our study sample correspondt ot h eh i g h e s ta n dl o w e s t
values of the Dutch disability weights for schizophrenia
[25], and all other BPRS-E values are spread linearly
across this range of DW values.
In the 1999 Thai Burden of Disease study, it was esti-
mated that 63% of cases were undergoing treatment and
37% were untreated, with an average GBD disability
weight of 0.452 [30]. We retained this assumption in
our current study because the mental health survey did
not collect information able to elicit this proportion. We
used the GBD DW for untreated patients, while the
three different measures of DW (Thai survey methods
b a s e do nE Q 5 D +a n dB P R Sa sw e l la sG B Dw e i g h t s )
were used for treated patients to get the possible range
of overall disease burden.
Burden of Disease
People with schizophrenia normally die from indirect
causes, such as an increased risk of suicide and lifestyle
Table 1 The number of community-based and hospitalized people with psychotic disorders and prevalence of
schizophrenia
Age Survey
participants
Surveyed cases of
psychosis
Estimated community-based prevalence
(percent)
a
Hospital-based prevalence
(percent)
a
Male Female Male Female Male Female Male Female
15-24 1,434 1,330 9 18 0.524 1.130 0.011 0.004
25-34 1,547 1,554 20 13 1.079 0.698 0.037 0.008
35-44 1,490 1,589 20 11 1.121 0.579 0.023 0.007
45-59 1,322 1,419 13 17 0.854 1.026 0.015 0.008
Total 5,793 5,889 62 59 0.900 0.848 0.022 0.007
a We adjusted the number of people with psychosis to estimate schizophrenia prevalence, using the ratio of 0.83 [16].
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Page 3 of 8risk factors leading to physical disorders (e.g., respiratory
and cardiovascular diseases). Therefore, there are no
deaths coded directly to schizophrenia and hence no
years of life lost (YLL) due to premature mortality but
only YLD contributing to DALY estimates of schizo-
phrenia [19,31]. There are two ways to compute YLD:
incident YLD and prevalent YLD [32,33]. A discount
rate of 3% was applied to incident YLD, but no GBD
age-weighting function was applied [3].
We calculated the uncertainty around YLD estimates
using the uncertainty surrounding the epidemiological
parameters and the DWs as input parameters. First, we
used the DisMod program, implementing a method
called “parametric bootstrapping” http://www.epigear.
com to generate multiple samples of modeled incidence,
prevalence, and disease duration. As input variables, we
defined a binomial distribution for survey prevalence
and remission (Table 1). A triangular distribution was
specified for the standardized mortality ratio. We ran
500 iterations, generating a range of results within
which we believed the true value would fall. Next, we
used Ersatz http://www.epigear.com to combine the
uncertainty around incidence and duration with that of
the disability weights to determine uncertainty ranges
around YLD.
Results
The majority of people with schizophrenia were in the
c o m m u n i t y( 9 8 % )( T a b l e1 ) .T h es u r v e yp r e v a l e n c eo f
schizophrenia in the Thai population aged between 15-
59 years in 2003 was 8.8 per 1,000 (95% CI: 7.2, 10.6)
with a male-to- female ratio of 1.1-to-1.
The modeled incidence rate was 0.3 per 1,000, with a
peak at ages 15-24 in both males and females (Table 2).
Prevalence peaked at ages between 30 and 44 in males
and at ages between 40 and 54 in females. The disease
duration in females was longer than in males across all
age groups due to greater life expectancy. The average
duration of schizophrenia was 30 and 34 years in men
and women, respectively.
Figure 1 Community-based prevalence estimates of psychotic disorders by age and sex and their 95% confidence intervals.
Table 2 Modeled incidence, prevalence, and disease duration by age groups and gender in 2005
Age group (years) Incidence per 1,000 Prevalence per 1,000 Duration (years)
male female male female male female
15-24 0.8 0.6 7.1 4.4 31 38
25-34 0.5 0.5 11.9 8.6 28 34
35-44 0.2 0.4 12.5 11 24 29
45-54 0 0.1 11.2 12 21 25
55-64 0 0 9.4 10.8 15 18
65+ 0 0 6.7 8.4 10 11
Overall 0.3 0.28 8.06 7.30 30 34
Male-to-female sex ratio 1.11 1.10
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very little variation by age or sex (Table 3). It was therefore
considered reasonable to use a single DW for all ages and
both sexes in our estimates. The local DWs were some-
what lower than the GBD-treated DW (Table 3).
Figures 2 and 3 show the age pattern of incident and
prevalent YLD with their 95% confidence intervals. Inci-
dent YLD was 75,000 (95% CI: 69,000, 83,000) in
women and 70,000 (95% CI: 64,000, 77,000) in men,
with the somewhat lower prevalence in women being
compensated by longer duration estimates. In 2005, pre-
valent YLD in men (110,000; 95% CI: 100,000, 120,000)
was marginally higher than in women (100,000; 95% CI:
96,000, 110,000), reflecting the higher prevalence in men
than in women.
Using DWs derived from local data or GBD assump-
tions had no significant impact on YLD estimates in
men or women (Figure 4).
Discussion
This is the first estimation of the burden of disease due
to schizophrenia in Thailand based on Thai prevalence
and severity data. It is also the first study undertaking
uncertainty analyses to determine the influence of
uncertain epidemiological variables on the burden of
disease from schizophrenia.
Table 3 Disability weights estimated based on different
approaches
Age Untreated
DW
Treated DW
GBD GBD EQ-5D+ BPRS
15-29 0.627 0.351 0.317 0.305
30-44 0.627 0.351 0.298 0.316
45-59 0.645 0.351 0.319 0.323
Total 0.627 0.351 0.308 (0.284 to
0.333)
a
0.316 (0.305 to
0.327)
Males 0.627 0.351 0.314 (0.282 to
0.345)
0.316 (0.300 to
0.332)
Females 0.627 0.351 0.299 (0.259 to
0.340)
0.316 (0.300 to
0.333)
a The 95% confidence intervals were estimated based on nonparametric
bootstrapping methods using Stata 10.0 (StataCorp, Texas, USA).
Figure 2 Incident and prevalent YLD in males and their 95% confidence intervals.
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Page 5 of 8Figure 3 Incident and prevalent YLD in females and their 95% confidence intervals.
Figure 4 Incident YLD across YLD using three disability weight estimates.
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Page 6 of 8Our prevalence estimate of 8.8 per 1,000 falls in the
highest decile of global prevalence figures reported in a
recent meta-analysis [1]. It is also higher than the preva-
lence ranges from 2.7 to 8.3 per 1,000 reported by two
other reviews [34,35]. It is, however, difficult to compare
our prevalence estimate with these other estimates for a
number of reasons: (1) differences in strategy for data
collection (community household surveys, register or
case note (institutionalized) information, or a combina-
tion of them); (2) differences in screening methods and
diagnostic criteria (ICD-10 and DSM-IV or an earlier
version of either classification system); (3) differences in
defined population (our estimate pertains to 15- to 59-
year-olds only); and (4) differences in field work plan-
ning (quality of training programs for interviewers). We
found no sex differential in prevalence. This is consis-
tent with the review study by Saha [1] and a recent
population-based survey in Finland [16]. Another mental
health survey was conducted in 2008. However, the final
results are not yet available. When data become avail-
able, they can be used to update these estimates.
T h eY L Do fs c h i z o p h r e n i aw e r eh i g h e ri nT h a i l a n d
than in the GBD studies in 2004 due to a higher Thai
prevalence estimate [36]. Using the data provided by
WHO, the average YLD of schizophrenia per capita
across the world and among Southeast Asian countries
was estimated to be 0.002 and 0.001, respectively [37],
while this study found YLD per capita of 0.004 in Thai-
l a n d .T h eG B Ds t u d yu s e dt h em e a np r e v a l e n c eo f
0.004. The disability burden in 2005 is lower than that
estimated in 1999 in total, with a higher burden in
females but lower in males [4]. However, the difference
in the data used limits comparison between the two stu-
dies. In 1999, a prevalence estimate of 7 per 1,000 in
men and 8 per 1,000 in women was based on expert
judgment. Less important are small differences in esti-
mates of remission and risk of mortality.
No other study has reported on DWs using individual
data on EQ-5D+ in the mental health area. The disabil-
ity weight derived from the BPRS was used in an Aus-
tralian economic evaluation study to calculate the
health gain from interventions [28,29], but no previous
study has incorporated this approach into burden of
disease. Despite local data giving smaller DWs than
those used in GBD studies, replacing universal weights
with the local weights does not significantly alter YLD.
Partly this is due to the fact that the relatively large
uncertainty around epidemiological parameters leads to
an overlap in estimates; the main explanation is that
our local DWs for treated schizophrenia were similar to
the disability weight for treated psychosis in GBD.
While the DALY approach has been criticized for using
expert panels to identify disease severity [11], our find-
ings suggest that experts, clinicians, and patients do not
rate the severity of treated schizophrenia very differ-
ently. The uncertainty around our prevalence estimates
was more important. Three additional factors were not
included in our quantification of uncertainty. First, the
mental health survey may have underestimated preva-
lence due to the stigma of schizophrenia. Second, using
a ratio of schizophrenia to total nonaffective psychotic
disorders from a Finnish study introduces further
uncertainty. Third, we assumed that people diagnosed
with schizophrenia were in either a hospital or in the
community, and that none of them was in both places
through the three-month survey period. However, since
data gathered by the Department of Mental Health sug-
gested that the average length of inpatient stay at psy-
chiatric hospitals in Thailand was 71 days in 2003 [38],
this assumption would be reasonable.
Conclusions
Sound epidemiological data, including incidence, preva-
lence, disability weight, and duration, are key factors in
estimating burden of disease. However, the results sug-
gest that an accurate estimate of the prevalence of schi-
zophrenia is more critical than the variation in disability
weights estimated from different perspectives.
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